Relmada Therapeutics, Inc. (NASDAQ:RLMD) CEO Sergio Traversa Buys 55,579 Shares

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CEO Sergio Traversa acquired 55,579 shares of the stock in a transaction dated Monday, September 9th. The stock was acquired at an average cost of $2.71 per share, with a total value of $150,619.09. Following the completion of the transaction, the chief executive officer now owns 299,603 shares in the company, valued at approximately $811,924.13. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Sergio Traversa also recently made the following trade(s):

• On Wednesday, September 11th, Sergio Traversa bought 51,407 shares of Relmada Therapeutics stock. The shares were acquired at an average price of $2.99 per share, for a total transaction of $153,706.93.

Relmada Therapeutics Trading Down 5.5 %

NASDAQ:RLMD opened at $3.09 on Friday. Relmada Therapeutics, Inc. has a 12 month low of $1.88 and a 12 month high of $7.22. The stock has a market capitalization of $93.23 million, a price-to-earnings ratio of -0.99 and a beta of 0.50. The firm has a fifty day simple moving average of $3.22 and a two-hundred day simple moving average of $3.77.

Relmada Therapeutics (NASDAQ:RLMD) last issued its earnings results on Wednesday, August 7th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.24. During the same period last year, the company earned ($0.84) earnings per share. Equities analysts predict that Relmada Therapeutics, Inc. will post -2.39 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, The Goldman Sachs Group lowered Relmada Therapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the company from $3.00 to $2.00 in a research note on Wednesday, June 5th.

Institutional Investors Weigh In On Relmada Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of RLMD. SG Americas Securities LLC bought a new position in shares of Relmada Therapeutics in the 1st quarter worth $53,000. State Board of Administration of Florida Retirement System acquired a new position in Relmada Therapeutics during the first quarter worth $70,000. American Century Companies Inc. raised its holdings in Relmada Therapeutics by 14.6% during the second quarter. American Century Companies Inc. now owns 31,618 shares of the company’s stock worth $95,000 after buying an additional 4,027 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Relmada Therapeutics in the fourth quarter valued at $243,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Relmada Therapeutics by 153.6% during the second quarter. Renaissance Technologies LLC now owns 88,775 shares of the company’s stock valued at $266,000 after buying an additional 53,767 shares during the last quarter. Institutional investors own 45.24% of the company’s stock.

About Relmada Therapeutics

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.